Chemicals

Amyris to Acquire Sweet Protein Specialist Oobli

Amyris is adding Oobli's fermentation-derived sweet proteins to its biomanufacturing platform, extending its reach into sugar reduction for food and beverage.

Imani NdlovuNovember 16, 20265 min read0 views
Rows of stainless-steel fermentation tanks in a bright production hall, with a glass vial of ingredient and a scatter of berries in the foreground.

Amyris, Inc., the Emeryville, Calif.-based vertically integrated biomanufacturing company, announced that it will acquire Oobli Inc. of Davis, Calif., a sweet protein innovator whose fermentation-based ingredients are used by food and beverage brands to reduce sugar while keeping taste.

The transaction combines Amyris' scientific capabilities and manufacturing depth with Oobli's protein fermentation expertise. It follows Amyris' expansion of manufacturing capacity earlier this year at its fermentation facility in Barra Bonita, Brazil, and is described by the company as a strategic commercial and technology expansion intended to accelerate its footprint in protein- and peptide-based solutions across end markets.

Complementary platforms

Chief executive officer Kathy Fortmann said the company sees in Oobli a commercial and technology platform that complements its own, adding that Oobli is positioned to change how sweetness reaches the market. Amyris expects its commercial scale and resources to speed that effort, and it sees potential to broaden its capabilities in food and beverage, personal care, flavor and fragrance, agriculture and other areas by combining Oobli's protein know-how with its strain engineering, manufacturing scale and commercial reach.

Oobli's commercial portfolio of sweet proteins is expected to be the first to benefit from the combined platform. The company has spent the past decade refining a fermentation process for producing sweet proteins that occur naturally in rare fruits and berries grown near the equator.

How the proteins work

According to the companies, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors, and are metabolized by the body as protein. On that basis they are presented as delivering sweetness without gut disruption or blood sugar spikes, and Oobli's products are described as the first of their kind in the sugar reduction category.

The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin. The company states that the ingredients hold FDA GRAS status and are FEMA GRAS-affirmed for use as a natural flavor. With consumer attention on metabolic health and sugar reduction growing, the proteins are positioned as a tool for cutting sugar across categories including sports and nutrition, dairy, beverages, chocolate, bakery and confectionery.

Oobli chief executive officer Ali Wing said the company had long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment, and described the combination with Amyris as providing the scale and resources to pursue its ambition of making sweet proteins a standard in sweetness solutions.

Fortmann added that Amyris has observed biomanufactured solutions succeeding when they align with consumer demand and market needs, and said Oobli's platform lets brands address sweet taste, sugar reduction and clean label at the same time.

The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships will continue to be honored without interruption as the sweet protein portfolio expands within the company.